Skip to main content

Compare Stocks

Date Range: 

 BenchmarkZomedicaAmryt PharmaThe Supreme CannabisHLS Therapeutics
SymbolLON:BMKNYSEAMERICAN:ZOMLON:AMYTTSE:FIRETSE:HLS
Price Information
Current PriceGBX 60.50$0.75GBX 166C$0.30C$17.23
52 Week RangeN/ABuyN/AN/ABuy
MarketRank™
Overall Score0.90.90.81.31.4
Analysis Score0.01.50.01.03.7
Community Score2.82.92.53.73.2
Dividend Score0.00.00.00.00.0
Ownership Score1.70.01.70.00.0
Earnings & Valuation Score0.00.00.01.90.0
Analyst Ratings
Consensus RecommendationN/ABuyN/AN/ABuy
Consensus Price TargetN/A$0.30N/AC$0.35C$30.50
% Upside from Price TargetN/A-59.74% downsideN/A18.64% upside77.02% upside
Trade Information
Market Cap£405.44 million$420.27 million£297.28 millionC$216.73 millionC$548.29 million
BetaN/AN/AN/AN/AN/A
Average Volume332,439138,504,656114,71211,037,56133,839
Sales & Book Value
Annual Revenue£109.90 millionN/A£186.46 millionC$49.44 millionC$56.53 million
Price / Sales3.69N/A1.594.389.70
CashflowGBX 8.54 per shareN/AGBX 63.92 per shareC$0.03 per shareC$0.74 per share
Price / Cash7.08N/A2.6011.1323.31
Book ValueGBX 42.30 per shareN/AGBX 29.60 per shareC$0.36 per shareC$5.29 per share
Price / Book0.01N/A0.060.823.26
Profitability
Net IncomeN/AN/AN/AN/AN/A
EPSGBX (4.30)N/AGBX (39.90)C($0.21)C($0.77)
Trailing P/E RatioN/A0.00N/AN/AN/A
Forward P/E Ratio∞∞∞∞∞
P/E GrowthN/AN/AN/A0.36N/A
Net MarginsN/AN/AN/AN/AN/A
Return on Equity (ROE)N/AN/AN/AN/AN/A
Return on Assets (ROA)N/AN/AN/AN/AN/A
Dividend
Annual PayoutN/AN/AN/AN/AC$0.15
Dividend YieldN/AN/AN/AN/A0.87%
Three-Year Dividend GrowthN/AN/AN/AN/AN/A
Payout RatioN/AN/AN/AN/AN/A
Years of Consecutive Dividend GrowthN/AN/AN/AN/AN/A
Debt
Debt-to-Equity Ratio37.33%N/A351.31%42.64%64.45%
Current Ratio3.51%N/A2.14%3.05%1.34%
Quick Ratio2.52%N/A1.73%1.53%0.98%
Ownership Information
Institutional Ownership PercentageN/AN/AN/AN/AN/A
Insider Ownership PercentageN/AN/AN/AN/AN/A
Miscellaneous
Employees8151916940088
Shares Outstanding670.15 million564.05 million179.09 million734.69 million31.82 million
Next Earnings Date5/18/2021 (Estimated)8/9/2021 (Estimated)8/4/2021 (Estimated)N/A8/5/2021 (Estimated)
OptionableNot OptionableNot OptionableNot OptionableNot OptionableNot Optionable
SourceHeadline
HLS Therapeutics (TSE:HLS) Given New C$28.00 Price Target at Raymond JamesHLS Therapeutics (TSE:HLS) Given New C$28.00 Price Target at Raymond James
americanbankingnews.com - May 10 at 3:04 PM
HLS Therapeutics (TSE:HLS) Rating Reiterated by Raymond JamesHLS Therapeutics (TSE:HLS) Rating Reiterated by Raymond James
americanbankingnews.com - May 4 at 3:04 PM
HLS Therapeutics (HLS) to Release Quarterly Earnings on ThursdayHLS Therapeutics (HLS) to Release Quarterly Earnings on Thursday
americanbankingnews.com - April 29 at 5:27 AM
HLS Therapeutics (TSE:HLS) Trading 2.1% Higher HLS Therapeutics (TSE:HLS) Trading 2.1% Higher
americanbankingnews.com - April 21 at 12:32 AM
Heres What Analysts Are Forecasting For HLS Therapeutics Inc. (TSE:HLS) After Its Annual ResultsHere's What Analysts Are Forecasting For HLS Therapeutics Inc. (TSE:HLS) After Its Annual Results
finance.yahoo.com - March 20 at 2:09 PM
HLS Therapeutics Announces Fourth Quarter and Fiscal 2020 Financial ResultsHLS Therapeutics Announces Fourth Quarter and Fiscal 2020 Financial Results
finance.yahoo.com - March 18 at 7:07 AM
HLS Therapeutics to Host Q4 and Fiscal 2020 Financial Results Conference CallHLS Therapeutics to Host Q4 and Fiscal 2020 Financial Results Conference Call
markets.businessinsider.com - March 4 at 6:56 AM
HLS Therapeutics to Participate in Virtual Non-Deal Roadshow on February 18, 2021HLS Therapeutics to Participate in Virtual Non-Deal Roadshow on February 18, 2021
finance.yahoo.com - February 16 at 5:03 PM
Saladax Biomedical Announces Health Canada Approval of Five MyCare™ Psychiatry Laboratory Diagnostic AssaySaladax Biomedical Announces Health Canada Approval of Five MyCare™ Psychiatry Laboratory Diagnostic Assay
benzinga.com - February 16 at 12:03 PM
HLS Therapeutics Provides Update on Private and Public Payer Reimbursement for Vascepa®HLS Therapeutics Provides Update on Private and Public Payer Reimbursement for Vascepa®
finance.yahoo.com - February 16 at 7:03 AM
VASCEPA® (Icosapent Ethyl) Receives Further Inclusions in Guidelines from International Medical Societies for its Role in Reducing the Risk of Cardiovascular EventsVASCEPA® (Icosapent Ethyl) Receives Further Inclusions in Guidelines from International Medical Societies for its Role in Reducing the Risk of Cardiovascular Events
finance.yahoo.com - January 28 at 8:46 AM
HLS Therapeutics Announces Update on Health Canada Filings for MyCare and TrinomiaHLS Therapeutics Announces Update on Health Canada Filings for MyCare and Trinomia
finance.yahoo.com - December 16 at 9:39 AM
HLS Therapeutics Establishes Automatic Share Purchase PlanHLS Therapeutics Establishes Automatic Share Purchase Plan
finance.yahoo.com - November 19 at 8:29 AM
VASCEPA® (Icosapent Ethyl) Found to Significantly Reduce Ischemic Events in Patients with Prior Coronary Artery Bypass Grafting ProceduresVASCEPA® (Icosapent Ethyl) Found to Significantly Reduce Ischemic Events in Patients with Prior Coronary Artery Bypass Grafting Procedures
finance.yahoo.com - November 16 at 7:58 AM
Do Institutions Own HLS Therapeutics Inc. (TSE:HLS) Shares?Do Institutions Own HLS Therapeutics Inc. (TSE:HLS) Shares?
finance.yahoo.com - November 8 at 12:45 PM
HLS Therapeutics Announces Q3 2020 Financial Results and Normal Course Issuer BidHLS Therapeutics Announces Q3 2020 Financial Results and Normal Course Issuer Bid
finance.yahoo.com - November 5 at 8:13 AM
SVB opens new office in CanadaSVB opens new office in Canada
pehub.com - October 29 at 6:37 PM
On-Demand Pharmaceuticals Printing at BattlefieldOn-Demand Pharmaceuticals Printing at Battlefield
i-hls.com - October 21 at 1:08 PM
HLS Therapeutics gets a target raise from Clarus SecuritiesHLS Therapeutics gets a target raise from Clarus Securities
cantechletter.com - October 2 at 12:41 PM
HLS Therapeutics Comments on U.S. Court of Appeals Decision in Amarin Patent LitigationHLS Therapeutics Comments on U.S. Court of Appeals Decision in Amarin Patent Litigation
finance.yahoo.com - September 3 at 2:11 PM
When Will HLS Therapeutics Inc. (TSE:HLS) Breakeven?When Will HLS Therapeutics Inc. (TSE:HLS) Breakeven?
finance.yahoo.com - August 10 at 1:28 PM
HLS Therapeutics misses on revenueHLS Therapeutics misses on revenue
seekingalpha.com - August 6 at 9:33 AM
HLS Therapeutics Announces Q2 2020 Financial ResultsHLS Therapeutics Announces Q2 2020 Financial Results
finance.yahoo.com - August 6 at 9:33 AM
HLS Therapeutics to Host Q2 2020 Financial Results Conference CallHLS Therapeutics to Host Q2 2020 Financial Results Conference Call
finance.yahoo.com - July 30 at 9:25 AM
HLS Therapeutics is undervalued, says StifelHLS Therapeutics is undervalued, says Stifel
www.cantechletter.com - July 24 at 1:11 PM
DateCompanyBrokerageAction
6/5/2019BenchmarkNumis SecuritiesReiterated Rating
11/12/2018BenchmarkKepler Capital MarketsReiterated Rating
11/16/2020ZomedicaHC WainwrightLower Price Target
5/5/2021Amryt PharmaShore CapitalReiterated Rating
5/18/2020Amryt PharmaBerenberg BankReiterated Rating
2/17/2021The Supreme CannabisCormarkBoost Price Target
5/10/2021HLS TherapeuticsRaymond JamesBoost Price Target
3/19/2021HLS TherapeuticsCanaccord GenuityBoost Price Target
7/21/2020HLS TherapeuticsBloom BurtonUpgrade
1/2/2020HLS TherapeuticsClarus SecuritiesReiterated Rating
(Data available from 5/15/2018 forward. View 10+ years of historical ratings with our analyst ratings screener.)
Comparison Ideas:

As Featured By:

MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.